Moberg discontinued development of Limtop after data from a double-blind, placebo-controlled, German Phase II trial in 97 patients with actinic keratosis showed that Limtop did not meet the predefined efficacy target. Moberg declined to disclose...

Moberg acquired its U.S. distributor Alterna for about SEK133 million ($20 million) in a cash and stock deal. Moberg issued Alterna SEK33 million ($4.9 million), or 825,625 shares, in Moberg stock and paid about SEK100...

Moberg completed enrollment of 97 patients in a double-blind, placebo-controlled, German Phase II trial evaluating topical Limtop given 1, 3 or 7 times weekly. Moberg Derma AB (SSE:MOB), Bromma, Sweden   Product: Limtop imiquimod  ...

Aftermarket performance is better for biotech IPOs this year than it was in 2011. Although the basics of what it takes to get an IPO done haven't changed - deals routinely continue to require a discount...

Moberg Derma began a double-blind, placebo-controlled, German Phase I trial to evaluate Limtop in 30 subjects. Moberg Derma AB (SSE:MOB), Bromma, Sweden   Product: Limtop   Business: Cancer, Dermatology, Infectious   Molecular target: NA  ...

Active Biotech AB (SSE:ACTI) gained SEK9.70 (24%) to SEK49.40 on Thursday after partner Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) said it plans to submit an MAA to EMA in 2H12 for laquinimod in multiple sclerosis (MS)....

Moberg said an analysis of about 50% of the patients in an open-label, Swedish Phase II trial of once-daily topical MOB-015 showed that there is a "low probability that the final results will be sufficient...

Even the best fundamentals may not be able to overcome the negative effects of the broader economy on the stock market this quarter. As a result, specialists have little hope of major gains and instead...

Moberg Derma completed enrollment of 237 patients in an open-label, Swedish Phase II trial evaluating once-daily topical MOB-015. Moberg Derma AB (SSE:MOB), Stockholm, Sweden   Product: MOB-015   Business: Infectious   Molecular target: NA  ...

Buysiders expect biotech may be able to continue to outperform the broader markets, despite a retreat from spring highs. In particular, they see two bright spots for the sector: selective gains on a full calendar...